Targeting OTUD6B in multiple myeloma (B05)

• Subject Area: Hematology, Oncology ; Pharmacy
• Term: since 2024
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 514894665

Multiple myeloma (MM) is the second most common hematological malignancy with adverse outcome despite recent therapeutic advances. We previously characterized the deubiquitylase (DUB) OTUD6B as a central vulnerability in MM that determines the proliferative state of this disease by stabilizing the RNA binding protein LIN28B. In addition to our functional studies, we performed compound screening and identified first OTUD6B activity inhibitors. Based on our previous results, we propose to further decipher the nature of the physiological OTUD6B-LIN28B complex, validate and chemically improve our OTUD6B inhibitors, and test advanced inhibitory molecules in cellular assays and in vivo to prove their efficacy on MM.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 387: Functionalizing the Ubiquitin System against Cancer - UbiQancer
• Applicant Institution: Technische Universität München (TUM)
• Project Heads: Professor Dr. Florian Bassermann; Dr. Kamyar Hadian, Ph.D.